List view / Grid view

Probiodrug AG



Probiodrug to present data on therapeutic concept of targeting pyro-Glu Abeta and its frontrunner QC-inhibitor PQ912 at International Alzheimer Conferences

17 November 2014 | By Probiodrug

Probiodrug AG, a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s Disease, announces that Prof. Hans-Ulrich Demuth, co- founder and consultant of Probiodrug, will be reviewing the target validation and summarize data on its lead product candidate PQ912 at two international conferences...